{"product_id":"global-stem-cell-umbilical-cord-blood-market-growth-status-and-outlook-2023-2029","title":"Global Stem Cell Umbilical Cord Blood Market Growth (Status and Outlook) 2023-2029","description":"\u003cp\u003eGlobal Stem Cell Umbilical Cord Blood Market Growth (Status and Outlook) 2023-2029\u003cbr\u003e\nUmbilical cord blood (UCB) stem cells have gained much significance in medical science owing to their ability to transform into any type of human cells. UCB refers to the blood that remains in the attached umbilical cord and placenta after childbirth. Stem cells that UCB contains are considered unique in their applicability in treating several life-threatening diseases. UCB stem cells are also used to treat genetic and hematopoietic disorders.\u003c\/p\u003e\n\n\u003cp\u003eLPI (LP Information)' newest research report, the “Stem Cell Umbilical Cord Blood Industry Forecast” looks at past sales and reviews total world Stem Cell Umbilical Cord Blood sales in 2022, providing a comprehensive analysis by region and market sector of projected Stem Cell Umbilical Cord Blood sales for 2023 through 2029. With Stem Cell Umbilical Cord Blood sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Stem Cell Umbilical Cord Blood industry.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report provides a comprehensive analysis of the global Stem Cell Umbilical Cord Blood landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M\u0026amp;A activity. This report also analyzes the strategies of leading global companies with a focus on Stem Cell Umbilical Cord Blood portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Stem Cell Umbilical Cord Blood market.\u003c\/p\u003e\n\n\u003cp\u003eThis Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Stem Cell Umbilical Cord Blood and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Stem Cell Umbilical Cord Blood.\u003c\/p\u003e\n\n\u003cp\u003eThe global Stem Cell Umbilical Cord Blood market size is projected to grow from US$ 18610 million in 2022 to US$ 131030 million in 2029; it is expected to grow at a CAGR of 32.2% from 2023 to 2029.\u003c\/p\u003e\n\n\u003cp\u003eIncrease in the prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. Has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.\u003c\/p\u003e\n\n\u003cp\u003eThis report presents a comprehensive overview, market shares, and growth opportunities of Stem Cell Umbilical Cord Blood market by product type, application, key players and key regions and countries.\u003c\/p\u003e\n\n\u003cp\u003eMarket Segmentation:\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by type\u003cbr\u003e\nPublic Cord Blood Banks\u003cbr\u003e\nPrivate Cord Blood Banks\u003c\/p\u003e\n\n\u003cp\u003eSegmentation by application\u003cbr\u003e\nCancer\/ Oncology Diseases\u003cbr\u003e\nChronic Leukemia\u003cbr\u003e\nMyelodysplastic Syndrome\u003cbr\u003e\nBlood Diseases\u003cbr\u003e\nBeta Thalassemia\u003cbr\u003e\nSickle Cell Disease\u003cbr\u003e\nWiskott-Aldrich\u003cbr\u003e\nHurler Syndrome\u003cbr\u003e\nSanfilippo Syndrome\u003c\/p\u003e\n\n\u003cp\u003eThis report also splits the market by region:\u003cbr\u003e\nAmericas\u003cbr\u003e\nUnited States\u003cbr\u003e\nCanada\u003cbr\u003e\nMexico\u003cbr\u003e\nBrazil\u003cbr\u003e\nAPAC\u003cbr\u003e\nChina\u003cbr\u003e\nJapan\u003cbr\u003e\nKorea\u003cbr\u003e\nSoutheast Asia\u003cbr\u003e\nIndia\u003cbr\u003e\nAustralia\u003cbr\u003e\nEurope\u003cbr\u003e\nGermany\u003cbr\u003e\nFrance\u003cbr\u003e\nUK\u003cbr\u003e\nItaly\u003cbr\u003e\nRussia\u003cbr\u003e\nMiddle East \u0026amp; Africa\u003cbr\u003e\nEgypt\u003cbr\u003e\nSouth Africa\u003cbr\u003e\nIsrael\u003cbr\u003e\nTurkey\u003cbr\u003e\nGCC Countries\u003c\/p\u003e\n\n\u003cp\u003eThe below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.\u003cbr\u003e\nAdvanced Cell Technology\u003cbr\u003e\nCalifornia Stem Cell\u003cbr\u003e\nCytori Therapeutics\u003cbr\u003e\nMesoblast Limited\u003cbr\u003e\nOpexa Therapeutics\u003cbr\u003e\nAthersys\u003cbr\u003e\nGeron Corporation\u003cbr\u003e\nNeostem\u003c\/p\u003e\n\n\u003cp\u003ePlease note: The report will take approximately 2 business days to prepare and deliver.\u003c\/p\u003e","brand":"Life Science","offers":[{"title":"February, 2023 \/ 85 Pages \/ MCW16227540","offer_id":47645971611954,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true},{"title":"February, 2023 \/ 85 Pages \/ MCW16227541","offer_id":47645971644722,"sku":null,"price":4392.0,"currency_code":"USD","in_stock":true}],"url":"https:\/\/www.hardmanwell.com\/products\/global-stem-cell-umbilical-cord-blood-market-growth-status-and-outlook-2023-2029","provider":"HARDMAN AND WELL MANAGEMENT CONSULTANCIES L.L.C","version":"1.0","type":"link"}